CATX on NYSE
Perspective Therapeutics, Inc.
American pharmaceutical preparations company based in Seattle.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with AVENUE THERAPEUTICS, INC., Cleveland BioLabs or Northwest Biotherapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
100.0%Gross margin3
-2855.0%Operating margin4
-3243.2%Net margin4
-61.9%Return on equity5
0.02×Debt to equity3
-$38.0MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development89¢$21.3M
- Interest0¢$84.0K
- Income tax11¢$2.7M
Out of $1.4M in revenue.34 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Grant revenue | $884.0K | $1.5M |
| Research and development | $84.2M | $41.6M |
| General and administrative | $30.2M | $26.6M |
| Goodwill impairment | $0 | $24.1M |
| Loss on disposal of property and equipment | $0 | $27.0K |
| Total operating expenses | $114.4M | $92.3M |
| Operating loss | -$113.6M | -$90.9M |
| Interest income | $8.1M | $10.5M |
| Interest and other expense | -$376.0K | -$48.0K |
| Other income from a related party (Note 3) | $1.4M | $0 |
| Equity in loss of affiliate | -$2.0K | -$8.0K |
| Total non-operating income, net | $9.1M | $10.5M |
| Net loss from continuing operations | -$104.4M | -$80.4M |
| Net gain (loss) from discontinued operations | $514.0K | -$949.0K |
| Net loss before deferred income tax benefit | -$103.9M | -$81.4M |
| Deferred income tax benefit | $793.0K | $2.1M |
| Net loss | -$103.1M | -$79.3M |
| Loss from continuing operations, Basic | -$1 | -$1 |
| Loss from continuing operations, Diluted | -$1 | -$1 |
| Gain (loss) from discontinued operations, Basic | $0 | -$0 |
| Gain (loss) from discontinued operations, Diluted | $0 | -$0 |
| Basic loss per share | -$1.40 | -$1.23 |
| Diluted loss per share | -$1.40 | -$1.23 |
| Basic | 73.8M shares | 64.4M shares |
| Diluted | 73.8M shares | 64.4M shares |
| Unrealized gain (loss) on available-for-sale securities | $161.0K | -$51.0K |
| Comprehensive loss | -$103.0M | -$79.3M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $30.6M | $61.6M | ||
| Short-term investments | $114.1M | $165.3M | ||
| Accounts receivable, net of allowance for doubtful accounts: $375 and $543 | $6.0K | $116.0K | ||
| Prepaid expenses and other current assets | $3.6M | $4.1M | ||
| Total current assets | $148.4M | $231.2M | ||
| Property and equipment, net | $76.6M | $57.3M | ||
| Right-of-use asset, net | $1.5M | $2.2M | ||
| Intangible assets, in-process research and development | $40.0M | $50.0M | $50.0M | |
| Other assets, net | $486.0K | $405.0K | ||
| Total assets | $267.0M | $341.1M | ||
| Accounts payable and accrued expenses | $20.5M | $10.3M | ||
| Lease liability | $623.0K | $957.0K | ||
| Accrued personnel expenses | $7.5M | $5.5M | ||
| Note payable | $56.0K | $52.0K | ||
| Deferred Income (Note 3) | $0 | $1.4M | ||
| Total current liabilities | $28.7M | $18.2M | ||
| Lease liability, net of current portion | $1.0M | $1.4M | ||
| Note payable, net of current portion | $1.6M | $1.6M | ||
| Deferred Income, net of current portion (Note 3) | $26.6M | $26.6M | ||
| Deferred tax liability | $1.7M | $2.5M | ||
| Other noncurrent liabilities | $386.0K | $55.0K | ||
| Total liabilities | $59.9M | $50.4M | ||
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | $0 | $0 | ||
| Common stock: $0.001 par value; authorized 750,000,000 shares; issued 74,337,990 and 70,671,464 shares | $74.0K | $70.0K | ||
| Additional paid-in capital | $541.7M | $522.4M | ||
| Accumulated other comprehensive income (loss) | $110.0K | -$51.0K | ||
| Accumulated deficit | -$334.8M | -$231.7M | ||
| Total stockholders' equity | $207.0M | $290.7M | $75.2M | |
| Total liabilities and stockholders' equity | $267.0M | $341.1M | ||
| Allowance for doubtful accounts | $375.0K | $543.0K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 7.0M shares | 7.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 74.3M shares | 70.7M shares | ||
| Common stock, shares outstanding | 74.3M shares | 70.7M shares | ||
| Reverse stock split, ratio | 0 pure |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $30.6M | $61.6M | ||
| Short-term investments | $114.1M | $165.3M | ||
| Accounts receivable, net of allowance for doubtful accounts: $375 and $543 | $6.0K | $116.0K | ||
| Prepaid expenses and other current assets | $3.6M | $4.1M | ||
| Total current assets | $148.4M | $231.2M | ||
| Property and equipment, net | $76.6M | $57.3M | ||
| Right-of-use asset, net | $1.5M | $2.2M | ||
| Intangible assets, in-process research and development | $40.0M | $50.0M | $50.0M | |
| Other assets, net | $486.0K | $405.0K | ||
| Total assets | $267.0M | $341.1M | ||
| Accounts payable and accrued expenses | $20.5M | $10.3M | ||
| Lease liability | $623.0K | $957.0K | ||
| Accrued personnel expenses | $7.5M | $5.5M | ||
| Note payable | $56.0K | $52.0K | ||
| Deferred Income (Note 3) | $0 | $1.4M | ||
| Total current liabilities | $28.7M | $18.2M | ||
| Lease liability, net of current portion | $1.0M | $1.4M | ||
| Note payable, net of current portion | $1.6M | $1.6M | ||
| Deferred Income, net of current portion (Note 3) | $26.6M | $26.6M | ||
| Deferred tax liability | $1.7M | $2.5M | ||
| Other noncurrent liabilities | $386.0K | $55.0K | ||
| Total liabilities | $59.9M | $50.4M | ||
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | $0 | $0 | ||
| Common stock: $0.001 par value; authorized 750,000,000 shares; issued 74,337,990 and 70,671,464 shares | $74.0K | $70.0K | ||
| Additional paid-in capital | $541.7M | $522.4M | ||
| Accumulated other comprehensive income (loss) | $110.0K | -$51.0K | ||
| Accumulated deficit | -$334.8M | -$231.7M | ||
| Total stockholders' equity | $207.0M | $290.7M | $75.2M | |
| Total liabilities and stockholders' equity | $267.0M | $341.1M | ||
| Allowance for doubtful accounts | $375.0K | $543.0K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 7.0M shares | 7.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 74.3M shares | 70.7M shares | ||
| Common stock, shares outstanding | 74.3M shares | 70.7M shares | ||
| Reverse stock split, ratio | 0 pure |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$103.1M | -$79.3M |
| Foreign currency adjustments | $250.0K | -$65.0K |
| Depreciation expense and amortization | $3.3M | $2.3M |
| Loss on disposal of property and equipment | $0 | $27.0K |
| Net accretion of discounts on available-for-sale securities | -$2.7M | -$607.0K |
| Loss on divestiture | $0 | $59.0K |
| Goodwill impairment | $0 | $24.1M |
| In-process research and development impairment | $10.0M | $0 |
| Share-based compensation | $9.0M | $5.4M |
| Deferred income tax benefit | -$793.0K | -$2.1M |
| Other, net | $5.0K | $99.0K |
| Accounts receivable | $110.0K | $1.0M |
| Inventory related to discontinued operations (Note 4) | $0 | $11.0K |
| Interest receivable | -$142.0K | -$880.0K |
| Prepaid expenses and other current assets | $624.0K | -$1.9M |
| Accounts payable and accrued expenses | $147.0K | $1.9M |
| Deferred Income | -$1.4M | $28.0M |
| Accrued personnel expenses | $2.0M | $3.6M |
| Other noncurrent liabilities | $331.0K | $55.0K |
| Net cash used in operating activities | -$82.5M | -$18.3M |
| Additions to property and equipment | -$12.7M | -$54.4M |
| Proceeds from the sale of property and equipment | $0 | $335.0K |
| Additions to other assets | -$135.0K | -$72.0K |
| Maturities of available-for-sale securities | $173.9M | $0 |
| Purchases of available-for-sale securities | -$119.8M | -$164.8M |
| Proceeds from maturity of held-to-maturity investments | $0 | $78.7M |
| Purchases of held-to-maturity investments | $0 | -$78.7M |
| Net cash provided by (used in) investing activities | $41.2M | -$218.9M |
| Repayment of notes payable | -$52.0K | -$48.0K |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | $0 | $125.0K |
| Proceeds from sales of common stock, pursuant to exercise of options | $371.0K | $1.3M |
| Proceeds from the sales of common stock and Pre-funded Warrants, net | $0 | $288.1M |
| Proceeds from the issuance of common stock pursuant to the ATM, net | $10.0M | $0 |
| Net cash provided by financing activities | $10.3M | $289.4M |
| Net (decrease) increase in cash and cash equivalents | -$31.0M | $52.2M |
| Property and equipment in accounts payable and accrued expenses | $9.8M | $0 |
| Recognition of operating lease liability and right-of-use asset | $205.0K | $2.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Perspective Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerJohan M. Spoor Feb 13, 2023 to now11
- Chief executive officerLori A. Woods Jun 19, 2018 to Nov 17, 202212
- Chief executive officerThomas C. Lavoy Feb 19, 2016 to Mar 2, 201813
- Chief executive officerDwight William Babcock May 19, 2008 to Nov 13, 201514
- Chief executive officerRoger Girard Aug 10, 2006 to Nov 13, 200715
- ChairThomas C. Lavoy Nov 21, 2017 to Mar 2, 201816
- PresidentRoger Girard Aug 10, 2006 to Nov 13, 200715
- Chief financial officerJuan Graham Jan 7, 2025 to Sep 5, 202517
- Chief financial officerJoel Sendek Sep 5, 2025 to now18
- Chief financial officerBrien Ragle Jul 8, 2014 to Jun 23, 201619
- Chief financial officerMichael Dunlop Nov 16, 2006 to Nov 16, 200620
- Chief operating officerJennifer Streeter Jun 25, 2020 to Jun 14, 202321
- Chief operating officerWilliam Cavanagh Jun 23, 2016 to Nov 16, 201822
- Chief operating officerLori A. Woods May 21, 2008 to Jun 10, 200923
Board members and other officers (25)
- Chief Medical OfficerMarkus Puhlmann Feb 13, 2023 to now24
- Dir. of Operations, SecretaryKrista Cline Sep 20, 2019 to Jun 25, 202025
- Principal Fin & Acct OfficerMatthew Branson Jan 26, 2017 to Jul 6, 201726
- VP of Human ResourcesJennifer Streeter Jun 29, 2017 to Jun 24, 201927
- Controller/Prin Fin&Acct OfficMark John Austin Jul 28, 2017 to Jul 19, 202428
- VP of Sales & MarketingMichael Krachon Jun 23, 2016 to Oct 28, 202029
- Vice PresidentFredric Swindler Oct 18, 2010 to Jul 2, 201430
- Vice PresidentWilliam Cavanagh Oct 18, 2010 to Aug 1, 202231
- ControllerBrien Ragle Oct 15, 2009 to Sep 12, 201332
- Vice PresidentLori A. Woods Mar 13, 2007 to Jun 6, 200733
- E.V.P.Operations & SecretaryDavid Swanberg Jul 17, 2006 to Feb 19, 200834
- Board memberFrank Morich Feb 13, 2023 to now35
- Board memberJohan M. Spoor Feb 13, 2023 to now11
- Board memberRobert F. Williamson Iii. Mar 17, 2023 to now36
- Board memberHeidi Henson Jun 2, 2023 to now37
- Board memberLori A. Woods Jun 19, 2018 to now12
- Board memberAlan Hoffmann Jan 19, 2016 to Jul 28, 202238
- Board memberMichael W. McCormick Jun 22, 2015 to Feb 23, 202339
- Board memberPhilip J. Vitale Jan 22, 2014 to Jul 28, 202240
- Board memberDwight William Babcock Jul 14, 2006 to Nov 13, 201541
- Board memberDavid Swanberg Jul 17, 2006 to Feb 19, 200834
- Board memberRoger Girard Aug 10, 2006 to Nov 13, 200715
- Board memberRobert R. Kauffman Aug 16, 2006 to Nov 20, 201242
- Board memberStephen Boatwright Aug 16, 2006 to Jun 5, 200743
- Board memberThomas C. Lavoy Aug 16, 2006 to Jun 29, 201744
Former names
Timeline
- Feb 13, 2023New chief executive Johan M. Spoor becomes CEO11
- Jun 19, 2018New chief executive Lori A. Woods becomes CEO12
- Feb 19, 2016New chief executive Thomas C. Lavoy becomes CEO13
- May 19, 2008New chief executive Dwight William Babcock becomes CEO14
- Aug 10, 2006New chief executive Roger Girard becomes CEO15
Filings
336 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 118 major events, 104 insider forms, 28 large holders, 3 private raises, 62 other. The latest 20:
- Oct 8, 20268-K EDGAR
- Oct 1, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Sep 8, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 8, 20268-K EDGAR
- Sep 4, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 4, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 2, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 3, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G EDGAR
- Jul 20, 2026SCHEDULE 13G EDGAR
- Jul 1, 20268-K EDGAR
- Jun 30, 2026SCHEDULE 13G EDGAR
- Jun 1, 20268-K EDGAR
- May 27, 20268-K EDGAR
The 336 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:
- Aug 13, 2026SCHEDULE 13G/A
- Aug 7, 2026SCHEDULE 13G
- Jul 29, 2026SCHEDULE 13G
- Jul 20, 2026SCHEDULE 13G
- Jun 30, 2026SCHEDULE 13G
- May 12, 2026SCHEDULE 13G/A
- Apr 27, 2026SCHEDULE 13G/A
- Mar 10, 2026SCHEDULE 13G
- Feb 12, 2026SCHEDULE 13G
- Feb 9, 2026SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 9,494,152 | $32.4M | 0.0% | +4,145,591 |
| TCG Crossover Management, LLC | 7,915,567 | $27.0M | 0.6% | No change |
| Commodore Capital LP | 6,336,782 | $21.6M | 1.3% | No change |
| Avidity Partners Management LP | 6,299,999 | $21.5M | 3.4% | −5,799,999 |
| State Street Corp | 6,051,771 | $20.6M | 0.0% | +2,919,101 |
| Millennium Management LLC | 4,911,855 | $16.7M | 0.0% | +865,215 |
| Nantahala Capital Management, LLC | 4,650,900 | $15.9M | 0.5% | New |
| Vanguard Capital Management LLC | 4,436,572 | $15.1M | 0.0% | +57,616 |
| Affinity Asset Advisors, LLC | 4,214,582 | $14.4M | 0.7% | +1,050,000 |
| Citadel Advisors LLC | 3,805,739 | $13.0M | 0.0% | +239,235 |
| Spruce Street Capital LP | 3,693,931 | $12.6M | 2.5% | +1,066,824 |
| Balyasny Asset Management L.P. | 3,320,224 | $11.3M | 0.0% | +325,764 |
| Geode Capital Management, LLC | 2,458,673 | $8.4M | 0.0% | +691,713 |
| Morgan Stanley | 1,912,550 | $6.5M | 0.0% | −1,070,792 |
| Goldman Sachs Group Inc | 1,733,078 | $5.9M | 0.0% | +491,262 |
| Nicholson Wealth Management Group, LLC | 1,619,993 | $5.5M | 3.3% | +1,000 |
| Two Sigma Investments, LP | 1,556,451 | $5.3M | 0.0% | +552,977 |
| ADAR1 Capital Management, LLC | 1,210,117 | $4.1M | 0.2% | +460,782 |
| Vanguard Portfolio Management LLC | 1,087,767 | $3.7M | 0.0% | +335,734 |
| Dimensional Fund Advisors LP | 1,074,071 | $3.7M | 0.0% | +623,974 |
| Yu Fan | 1,055,409 | $3.6M | 3.3% | No change |
| Hills Bank & Trust Co | 872,200 | $3.0M | 0.1% | No change |
| Northern Trust Corp | 791,774 | $2.7M | 0.0% | +262,846 |
| Charles Schwab Investment Management Inc | 773,262 | $2.6M | 0.0% | +111,944 |
| Ally Bridge Group (NY) LLC | 743,958 | $2.5M | 3.3% | −182,599 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARThomas C. Lavoy, Chair
- 17SEC EDGARJuan Graham, Chief financial officer
- 18SEC EDGARJoel Sendek, Chief financial officer
- 19SEC EDGARBrien Ragle, Chief financial officer
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30SEC EDGARFredric Swindler, Vice President
- 31SEC EDGARWilliam Cavanagh, Vice President
- 32SEC EDGARBrien Ragle, Controller
- 33SEC EDGARLori A. Woods, Vice President
- 34
- 35SEC EDGARFrank Morich, Board member
- 36
- 37SEC EDGARHeidi Henson, Board member
- 38SEC EDGARAlan Hoffmann, Board member
- 39SEC EDGARMichael W. McCormick, Board member
- 40SEC EDGARPhilip J. Vitale, Board member
- 41SEC EDGARDwight William Babcock, Board member
- 42SEC EDGARRobert R. Kauffman, Board member
- 43SEC EDGARStephen Boatwright, Board member
- 44SEC EDGARThomas C. Lavoy, Board member